ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma | The Johns Hopkins University School of Medicine / David Loeb, MD, PhD | Reach Grants | 2013 | Maryland |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition | Children’s Hospital of Philadelphia / Yael Mossé, MD | Reach Grants | 2013 | Pennsylvania |
Targeting a Novel Epigenetic Signature in Diffuse Intrinsic Pontine Gliomas | New York University School of Medicine / Danny Reinberg, PhD | Reach Grants | 2019 | New York |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations | The Regents of the University of Michigan / Jolanta Grembecka, PhD | Reach Grants | 2022 | Michigan |
Dual PTK7/GD2 Gamma Delta CAR T Cell Therapy for Neuroblastoma | Emory University / Kelly Goldsmith, MD & H. Trent Spencer, PhD & Chris B. Doering, PhD | Reach Grants | 2021 | Georgia |
Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia | Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD | Reach Grants | 2015 | Massachusetts |
Epigenomics of High Risk Pediatric T Cell Leukemia | New York University School of Medicine / Iannis Aifantis, PhD | Reach Grants | 2013 | New York |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias | National Cancer Institute / Andre Nussenzweig, Ph.D. | Reach Grants | 2014 | Maryland |
Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma | Van Andel Research Institute / Patrick Grohar, MD, PhD | Reach Grants | 2013 | Michigan |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen | Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. | Reach Grants | 2014 | New York |